Nataliya Kovalchuk, Clinical Professor at Stanford Radiation Oncology, shared a post on LinkedIn:
“ASTRO25: Exciting findings from the NRG-GU005 trial!
This study compared SBRT (36.25 Gy in 5 fx) to moderately hypofractionated IMRT in patients with localized intermediate-risk prostate cancer.
Key Takeaways:
- HRQOL Results: SBRT showed significantly fewer patients experiencing declines in bowel health-related quality of life (HRQOL) compared to M-IMRT (34.9% vs. 43.8%, p=0.034)!
- Urinary Outcomes: No significant difference in urinary health-related quality of life between the two treatments.
- DFS Insights: Unfortunately, no improvement in disease-free survival for SBRT over M-IMRT was observed at the 3-year mark (SBRT: 88.6% vs. IMRT: 92.1%).
- Biochemical failure at 3 year: SBRT 8% vs 4%
Per discussant, PACE-B prescriprion of 40Gy might be preferrable.”
Read more posts featuring Nataliya Kovalchuk on OncoDaily.